


Mycoses.
DUP - General Collection
W1 MY735H
v. 52, no. 1
Jan. 2009

2009

mycoses

Diagnosis, Therapy and Prophylaxis of Fungal Diseases
Official Publication of Deutschsprachige Mykologische Gesellschaft



PROPERTY OF THE
NATIONAL
LIBRARY OF
MEDICINE

An online version is available at

www.ijm.de/acknowled

**DOCKET
ALARM**

Find authenticated court documents without watermarks at docketalarm.com.

mycoses

Diagnosis, Therapy and Prophylaxis of Fungal Diseases

Official Publication of Deutschsprachige Mykologische Gesellschaft

ABSTRACTED/INDEXED IN: BIOSIS database; CAB Abstracts; Review of Medical and Veterinary Mycology; Cambridge Scientific Abstracts; Microbiology Section C; Chemical Abstracts; Current Contents/Life Sciences; Derwent Drug File; Elsevier BIOBASE/Current Awareness in Biological Sciences; EMBASE/ Excerpta Medica; Index Medicus; Index Veterinarius; MEDLINE; PASCAL; Research Alert; Science Citation Index; SciSearch; SUBIS Current Awareness in Biomedicine; Veterinary Bulletin; VINITI/ Russian Academy of Science.

PUBLISHER

Blackwell Verlag GmbH
Wiley-Blackwell
Rotherstrasse 21
10245 Berlin, Germany
phone: +49 30 470 31-400, fax: +49 30 470 31-410
Internet Homepage: www.blackwell.de
Blackwell Verlag is now part of John Wiley & Sons.

EDITOR-IN-CHIEF

Professor Dr. Hans Christian Korting

EDITORIAL OFFICE

Erika Ratzinger
Vohlbürgerstraße 13
D-80687 München, Germany
phone: +49 89 546 624 35, fax: +49 89 583 824
e-mail: mycoses.muenchen@t-online.de

SUBMISSION OF MANUSCRIPTS

Manuscripts should be submitted online at <http://mc.manuscriptcentral.com/myc>. Full instructions are provided on the site.

JOURNAL PUBLISHING MANAGER

Klaus Mickus
phone: +49 30 470 31-450
e-mail: kmickus@wiley.com

PRODUCTION EDITOR

Simon Tan
phone: +65 6511 8237, fax: +65 6511 8288
e-mail: myc@oxon.blackwellpublishing.com

OFFPRINTS. For information regarding offprints please contact:

offprint@cosprinters.com
Commercial offprints: bbeyer@wiley.com

TYPESETTING. Scientific Publishing Services, Chennai, India

IMPRINT DETAILS. Printed in Singapore by Markono Print Media Pte Ltd

ISSN 0933-7407 (Print)
ISSN 1439-0507 (Online)

INFORMATION FOR SUBSCRIBERS. *mycoses* is published in six issues per year. Subscription prices for 2009 are: Premium Institutional: £447 (Europe), US\$789 (The Americas), US\$921 (Rest of World); Personal: €272 (Europe, Euro zone), US\$352 (The Americas), £210 (Rest of World). Members of the DMykG: €204 (Europe). Prices are exclusive of tax. Australian GST, Canadian GST and European VAT will be applied at the appropriate rates. For more information on current tax rates, please go to www.wiley.com, click on Help and follow the link through to Journal

subscriptions. The Premium institutional price includes online access to the current and all online back files to January 1st 1977, where available. For other pricing options, including access information and terms and conditions, please visit www.interscience.wiley.com/journals

DELIVERY TERMS AND LEGAL TITLE. Prices include delivery of print journals to the recipient's address. Delivery terms are Delivered Duty Unpaid (DDU); the recipient is responsible for paying any import duty or taxes. Legal title passes to the customer on despatch by our distributors.

PERIODICAL ID STATEMENT. MYCOSES (ISSN: 0933-7407) is published bimonthly. US mailing agent: Mercury Airfreight International Inc., 365 Blair Road, Avenel, NJ 07001, USA. Periodical postage paid at Rahway, NJ. POSTMASTER: Send all address changes to MYCOSES, Journal Customer Services, John Wiley & Sons Inc., 350 Main St., Malden, MA 02148-5020.

JOURNAL CUSTOMER SERVICES. For ordering information, claims and any enquiry concerning your journal subscription please contact your nearest office:

UK: Email: customerservices@blackwellpublishing.com;

Tel: +44 (0) 1865 778315; Fax: +44 (0) 1865 471775

USA: Email: customerservices@blackwellpublishing.com;

Tel: +1 781 388 8599 or 1 800 835 6770 (Toll free in the USA & Canada); Fax: +1 781 388 8232 or Fax: +44 (0) 1865 471775

Asia: Email: customerservices@blackwellpublishing.com;

Tel: +65 6511 8000; Fax: +44 (0) 1865 471775

BACK ISSUES. Single issues from current and recent volumes are available at the current single issue price from customerservices@blackwellpublishing.com. Earlier issues may be obtained from Periodicals Service Company, 11 Main Street, Germantown, NY 12526, USA. Tel: +1 518 537 4700. Fax: +1 518 537 5899. Email: psc@periodicals.com

COPYRIGHT AND PHOTOCOPYING. Journal compilation © 2009 Blackwell Publishing Ltd. All rights reserved. No part of this publication may be reproduced, stored or transmitted in any form or by any means without the prior permission in writing from the copyright holder. Authorization to photocopy items for internal and personal use is granted by the copyright holder for libraries and other users registered with their local Reproduction Rights Organisation (RRO), e.g. Copyright Clearance Center (CCC), 222 Rosewood Drive, Danvers, MA 01923, USA (www.copyright.com), provided the appropriate fee is paid directly to the RRO. This consent does not extend to other kinds of copying such as copying for general distribution, for advertising and promotional purposes, for creating new collective works or for resale. Special requests should be addressed to: jrights@wiley.com

DISCLAIMER. The Publisher and Editors cannot be held responsible for errors or any consequences arising from the use of information contained in this journal; the views and opinions expressed do not necessarily reflect those of the Publisher and Editors, neither does the publication of advertisements constitute any endorsement by the Publisher and Editors of the products advertised.

This journal is available online. Visit www3.interscience.wiley.com to search the articles and register for table of contents e-mail alerts.

For submission instructions, subscription and all other information visit: www.blackwellpublishing.com/myc

mycoses

Diagnosis, Therapy and Prophylaxis of Fungal Diseases

Official Publication of Deutschsprachige Mykologische Gesellschaft

VOLUME 52

JANUARY 2009

NUMBER 1

CONTENTS

REVIEW ARTICLES

M. Kruppa. Quorum sensing and *Candida albicans* 1

S. R. Torres, A. Garzino-Demo, T. F. Meiller, V. Meeks, M. A. Jabra-Rizk. Salivary histatin-5 and oral fungal colonisation in HIV+ individuals 11

ORIGINAL ARTICLES

M. C. Esposto, M. Cogliati, A. M. Tortorano, M. A. Viviani. Electrophoretic karyotyping of *Cryptococcus neoformans* AD-hybrid strains 16

X. P. Liu, S. R. Fan, F. Y. Bai, J. Li, Q. P. Liao. Antifungal susceptibility and genotypes of *Candida albicans* strains from patients with vulvovaginal candidiasis 24

I. Fidan, A. Kalkanci, E. Yesilyurt, B. Yalcin, B. Erdal, S. Kustimur, T. Imir. Effects of *Saccharomyces boulardii* on cytokine secretion from intraepithelial lymphocytes infected by *Escherichia coli* and *Candida albicans* 29

M. A. Ghannoum, L. Long, W. R. Pfister. Determination of the efficacy of terbinafine hydrochloride nail solution in the topical treatment of dermatophytosis in a guinea pig model 35

C. P. Girish Kumar, T. Menon, S. Rajasekaran, B. Sekar, D. Prabu. Carriage of *Candida* species in oral cavities of HIV infected patients in South India 44

I. A. Aridogan, M. Ilkit, V. Izol, A. Ates, H. Demirhindi. Glans penis and prepuce colonisation of yeast fungi in a paediatric population: pre- and postcircumcision results 49

A. G. Luque, M. S. Biasoli, M. E. Tosello, A. Binolfi, S. Lupo, H. M. Magaró. Oral yeast carriage in HIV-infected and non-infected populations in Rosario, Argentina 53

J. P. Talarmin, D. Boutoille, P. Tattevin, P. Abgueguen, S. Ansart, F. Roblot, F. Raffi. *Candida* endocarditis: role of new antifungal agents 60

C. Romano, L. Massai, A. Gallo, M. Fimiani. *Microsporium gypseum* infection in the Siena area in 2005–2006 67

Y. Takahata, M. Hiruma, Y. Shiraki, Y. Tokuhisa, T. Sugita, M. Muto. Treatment of dermatophyte onychomycosis with three pulses of terbinafine (500 mg day⁻¹ for a week) 72

LETTERS TO THE EDITOR

C. Serrano Falcón, M. del Mar Serrano Falcón, J. Delgado Ceballos, V. Delgado Florencio, V. Crespo Erchiga, S. Serrano Ortega. Onychomycosis by *Chaetomium* spp. 77

R. Kano, K. Edamura, H. Yumikura, H. Maruyama, K. Asano, S. Tanaka, A. Hasegawa. Confirmed case of feline mycetoma due to *Microsporium canis* 80

A. Akyol Erikci, M. Ozyurt, H. Terekci, A. Ozturk, O. Karabudak, K. Oncu. Oesophageal aspergillosis in a case of acute lymphoblastic leukaemia successfully treated with caspofungin alone due to liposomal amphotericin B induced severe hepatotoxicity	84
T.-A. Vyzantiadis, A. Kioumi, E. Papadakis, M. Braimi, E. Dermitzakis, I. Tsitouridis, A. Antoniadis. Rhino-cerebral zygomycosis resistant to antimycotic treatment: a case report	87
S. Verghese, T. Chellamma, K. M. Cherian. Osteomyelitis of the rib caused by <i>Aspergillus flavus</i> following cardiac surgery	91
Book Review	94
Corrigenda	95
Congress Calendar	97

CAPTION OF THE COVER ILLUSTRATION. Histopathological analysis of skin from untreated control (a) and guinea pigs treated with terbinafine HCl nail solutions (TNS) (terbinafine HCl 1%, dodecyl-2-N,N-dimethylaminopropionate hydrochloride 5%) (b). Sections were stained with Grocott Methenamine Silver stain. As can be seen in (a), dark-coloured Trichophyton mentagrophytes hyphae were present (arrows) in the stratum corneum of the epidermis and (b) shows the structure of intact skin from TNS-treated animals. See M. A. Ghannoum *et al.*, Determination of the efficacy of terbinafine hydrochloride nail solution in the topical treatment of dermatophytosis in a guinea pig model, pp. 35–43 in this issue.

Determination of the efficacy of terbinafine hydrochloride nail solution in the topical treatment of dermatophytosis in a guinea pig model

Mahmoud A. Ghannoum,^{1,2} Lisa Long¹ and William R. Pfister³

¹Center for Medical Mycology, Case Western Reserve University, Cleveland, ²University Hospitals of Cleveland, Cleveland, OH and ³NexMed Inc., East Windsor, NJ, USA

Summary

Currently available topical antifungals are often not satisfactory for the treatment of nail infections, because of the inability to penetrate the nail plate. Terbinafine HCl nail solution is a novel antifungal formulation containing a nail penetration enhancer dodecyl-2-*N,N*-dimethylaminopropionate hydrochloride (DDAIP HCl, trade name NexACT[®]-88). In this study, we used a guinea pig model of *Trichophyton mentagrophytes* dermatophytosis and evaluated the clinical and mycological efficacy of different terbinafine HCl nail solutions (TNS) formulated with or without DDAIP HCl. Ciclopirox (8%) nail lacquer (Penlac[®]), the only Food and Drug Administration approved topical treatment for onychomycosis, was used as a comparator. Following the IACUC Guidelines, the skin of male albino guinea pigs was abraded under anaesthesia. Each animal was infected with *T. mentagrophytes* ATCC 24953 (cell suspension containing 1×10^7 conidia). The experimental animals were divided into 11 groups (five animals per group) and tested with the following formulations: vehicle control, 0.5% DDAIP HCl, 1%, 5% and 10% TNS (without DDAIP HCl), 1% TNS with 0.5%, 2.5% and 5.0% DDAIP HCl, 5% and 10% TNS with 0.5% DDAIP HCl, 8% ciclopirox nail lacquer and an untreated control group. Evaluation of clinical and mycological efficacy was performed 72 h after completion of a 7-day treatment regimen. Skin biopsy samples were processed for histopathological examination. The infected untreated control guinea pigs showed patches of hair loss and ulcerated or scaly skin and fungal invasion of hair roots. The vehicle and 0.5% DDAIP HCl treated groups showed minimal clinical efficacy (only 11% and 5%, respectively). In contrast, all three concentrations of TNS (1%, 5% and 10% terbinafine HCl) formulated with or without 0.5% DDAIP HCl showed 100% mycological efficacy by the hair root invasion test. Clinical efficacy of the 5% and 10% TNS improved with addition of 0.5% DDAIP HCl (47.4% and 73.8% vs. 68.4% and 89.5%, respectively). In addition, no fungal elements were detected in the treated guinea pig skin. All formulations of TNS resulted in a higher clinical and mycological efficacy compared with the 8% ciclopirox nail lacquer ($P = 0.0444$). In conclusion, TNS containing 1%, 5% and 10% terbinafine HCl formulated with and without DDAIP HCl demonstrated high antifungal efficacy in experimental dermatophytosis. Addition of 0.5% DDAIP HCl to 5% and 10% TNS significantly enhanced the clinical and mycological efficacy of these formulations which were superior compared with the 8% ciclopirox nail lacquer. Evaluation of the 1%, 5% and 10% TNS in clinical trials for the treatment of dermatophytosis and onychomycosis is warranted.

Correspondence: Mahmoud A. Ghannoum, Center for Medical Mycology, Case Western Reserve University and University Hospitals of Cleveland, 11100 Euclid Avenue, Cleveland, OH 44106-5028, USA. Tel.: +1 216 844 8580. Fax: +1 216 844 1076. E-mail: mahmoud.ghannoum@case.edu

Accepted for publication 25 March 2008

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.